Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cartesian Therapeutics (RNAC) has issued an update.
At the 2024 Annual Meeting of Cartesian Therapeutics, Inc., stockholders ratified significant proposals, including the election of two Class II Directors, the approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the year. Additionally, they approved the Amended and Restated 2016 Incentive Award Plan, which aims to incentivize employees with awards linked to the company’s performance, enhancing their dedication to the company’s growth and success.
Find detailed analytics on RNAC stock on TipRanks’ Stock Analysis page.
